Autolus Therapeutics plc ADR (NASDAQ:AUTL) shares, rose in value on Wednesday, February 12, with the stock price up by 2.62% to the previous day’s close as strong demand from buyers drove the stock to $1.96.
Actively observing the price movement in the last trading, the stock closed the session at $1.91, falling within a range of $1.895 and $1.98. Referring to stock’s 52-week performance, its high was $7.37, and the low was $1.87. On the whole, AUTL has fluctuated by -14.78% over the past month.
With the market capitalization of Autolus Therapeutics plc ADR currently standing at about $521.60 million, investors are eagerly awaiting this quarter’s results, scheduled for in March.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 2.98M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that AUTL’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of AUTL currently trading nearly -9.09% and -18.91% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 35.67, while the 7-day volatility ratio is showing 5.82% which for the 30-day chart, stands at 5.75%. Furthermore, Autolus Therapeutics plc ADR (AUTL)’s beta value is 2.04, and its average true range (ATR) is 0.13.
A comparison of Autolus Therapeutics plc ADR (AUTL) with its peers suggests the former has fared considerably weaker in the market. AUTL showed an intraday change of 2.62% in last session, and over the past year, it shrunk by -69.28%%.
Data on historical trading for Autolus Therapeutics plc ADR (NASDAQ:AUTL) indicates that the trading volumes over the past 10 days have averaged 1.19 and over the past 3 months, they’ve averaged 1.58 million. According to company’s latest data on outstanding shares, there are 266.12 million shares outstanding.
Nearly 11.06% of Autolus Therapeutics plc ADR’s shares belong to company insiders and institutional investors own 56.50% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 9.11 million shares as on 2025-01-31, resulting in a short ratio of 8.28. According to the data, the short interest in Autolus Therapeutics plc ADR (AUTL) stood at 462.00 of shares outstanding as of 2025-01-31; the number of short shares registered in 2024-12-31 reached 8.63 million. The stock has fallen by -16.60% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the AUTL stock heading into the next quarter.
